Jeffrey Dobson

Jeffrey Dobson has a diverse work experience spanning over two decades. Jeffrey began their career at Enterprise Rent-A-Car, where they worked as a Remarketing/Rental professional from 1996 to 2003. Jeffrey then transitioned into the pharmaceutical industry, holding various roles at Schering-Plough Pharmaceuticals, Gilead Sciences, and United Therapeutics.

At Schering-Plough Pharmaceuticals, Jeffrey worked as a Sales Representative from 2005 to 2008. Jeffrey then joined Gilead Sciences as a Therapeutic Specialist II, a role they held from 2008 to 2010. Subsequently, they moved to United Therapeutics, where they served as a Senior Institutional CardioPulmonary Specialist from 2010 to 2015.

Jeffrey's pharmaceutical career continued with roles at BioMarin Pharmaceutical Inc. Jeffrey started as a Rare Disease Account Manager from 2015 to 2016 and then advanced to become an Institutional Account Manager from 2016 to 2017. Following that, they joined Strongbridge Biopharma plc as an Area Business Specialist from 2017 to 2018, and then RareGen LLC as a Rare Disease Specialist from 2018 to 2020.

In 2020, Jeffrey joined Alnylam Pharmaceuticals as a Business Account Executive, a position they held until 2022. Currently, they are working at Liquidia Corporation as a Regional Business Director, a role they assumed in August 2022.

Throughout their career, Jeffrey Dobson has gained extensive experience in the pharmaceutical and biotechnology sectors, showcasing their expertise in account management, sales, and specialty diseases.

Jeffrey Dobson attended Wabash College from 1991 to 1993, where they did not earn a degree or specify a field of study. Jeffrey then pursued a Bachelor of Arts degree in Psychology at Indiana University Bloomington from 1993 to 1996, successfully completing their degree.